Acne News and Research

Latest Acne News and Research

Acupuncture and exercise help women with PCOS

Acupuncture and physical exercise improve hormone levels and menstrual bleeding pattern in women with polycystic ovary syndrome (PCOS), reveals research from the University of Gothenburg, Sweden.

7 Feb 2011

Stiefel introduces BPO Acne Creamy Washes for OTC use in the U.S.

Stiefel, a GSK company, today announced the launch of the most-prescribed BPO Acne Wash formulations for over-the-counter use in the United States.

5 Feb 2011

Palomar Medical Technologies to launch Acleara acne clearing system at AAD meeting

Palomar Medical Technologies, Inc., a leading researcher and developer of light-based systems for cosmetic treatments, announced today the launch of the Acleara acne clearing system at the 69th Annual Meeting of the American Academy of Dermatology in New Orleans, Louisiana, from February 5th through February 7th.

5 Feb 2011

Proper skin care, cosmetics can improve skin of acne and rosacea patients

Patients with acne and rosacea are often confused about selecting appropriate skin care products, cosmeceuticals and cosmetics to add into their daily routine. While they want to continue to see results with the treatment regimen from their dermatologist, they also want to be comfortable using products that address other skin issues, such as wrinkles or that protect their skin, such as sunscreens.

5 Feb 2011

Positive results from Photocure's Allumera RevitAll study to improve skin's appearance

Photocure, a Norwegian specialty pharmaceutical company focused in dermatology and cancer, today announced positive results from its consumer trial with Allumera™, a breakthrough cosmetic treatment formulated to improve the skin's appearance.

4 Feb 2011

NINDS awards AndroScience $3.8M cooperative translational research grant for Kennedy's Disease

AndroScience Corp., based in San Diego, California, announced receiving a $3.8 Million, 3-year milestone-driven, cooperative translational research grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH).

25 Jan 2011

New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today highlighted a further analysis of the large randomized Phase II OPUS study demonstrating an association between early tumor shrinkage and long-term median overall survival (OS) of more than 2 years for patients with KRAS wild-type metastatic colorectal cancer (mCRC) treated with Erbitux® (cetuximab) plus FOLFOX standard chemotherapy.

19 Jan 2011

Women with PCOS face high risk of type 2 diabetes due to aberrations in fat tissue

A study from the University of Gothenburg, shows that women with polycystic ovary syndrome (PCOS) have aberrations in their adipose tissue.

17 Jan 2011

FDA accepts to review Fibrocell Science's azficel-T drug

Fibrocell Science, a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that the U.S. Food & Drug Administration has accepted for review the Company's complete response submission for azficel-T, proposed brand name laViv, for the treatment of moderate to severe nasolabial folds and wrinkles.

12 Jan 2011

Acne bacterium may also cause infections all over the body

A bacterium which causes acne and is commonly found on the skin, is now known to cause infections all over the body. Propionibacterium acnes (P. acnes)5 has been associated with infections of artificial joints and heart valves (endocarditis), as well as eye infections and chest infections - which are common at this time of year.

12 Jan 2011

KYTHERA and Intendis initiate ATX-101 European Phase III studies for reduction of submental fat

KYTHERA Biopharmaceuticals, Inc. and Intendis, Bayer HealthCare's dermatology business, today announced the initiation of two European Phase III studies evaluating ATX-101, a first-in-class injectable adipolytic agent, for the reduction of localized fat under the chin (submental fat).

10 Jan 2011

FDA approves Impax's ANDA for generic Doryx 75 and 100mg tablets

Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company's Abbreviated New Drug Application for the generic version of Doryx® (doxycyline hyclate delayed-release) 75 and 100mg tablets. The Company is preparing for product launch through Global Pharmaceuticals, Impax's generic division.

29 Dec 2010

Study finds specially designed probiotic can prevent obesity

Specially designed probiotics can modulate the physiology of host fat cells say scientists writing in Microbiology. The findings could lead to specialised probiotics that have a role in the prevention or treatment of conditions such as obesity.

22 Dec 2010

Fibrocell Science submits response to FDA CR letter for azficel-T BLA

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted its complete response to the Complete Response (CR) letter issued by the U.S. Food & Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) for azficel-T, proposed brand name laViv®, for the treatment of moderate to severe nasolabial folds and wrinkles.

20 Dec 2010

Bayer's SAFYRAL oral contraceptive receives FDA approval

Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL™ (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL raises folate levels for the purpose of reducing the risk of rare neural tube defects (NTDs) in a pregnancy conceived while taking SAFYRAL or shortly after discontinuing it.

17 Dec 2010

Boehringer Ingelheim reports positive results from afatinib phase IIb/III LUX-Lung 1 trial in advanced NSCLC

Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs. 1.0 month for placebo) in progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients most likely to have an epidermal growth factor receptor (EGFR) mutation. The updated LUX-Lung 1 data will be presented at the Chicago Multidisciplinary Symposium in Thoracic Oncology.

13 Dec 2010

Cipher Phase 3 dermatology study uses MedAvante Centralized Ratings

MedAvante, Inc., the leader in centralized expert evaluation of treatments for central nervous system disorders, announced that Cipher Pharmaceuticals is using MedAvante Centralized Ratings in their pivotal Phase 3 dermatology study.

8 Dec 2010

NovaBay Pharmaceuticals, Galderma expand their multi-year collaboration agreement

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, and Galderma, a global leading pharmaceutical company dedicated exclusively to the field of dermatology, announce the expansion of their multi-year collaboration agreement. Based on positive data assessing the activity of NovaBay's Aganocide compounds against impetigo, Galderma has agreed to exercise its option for this indication.

6 Dec 2010

Bill & Melinda Gates Foundation awards $6M grant to NanoBio to develop intranasal vaccine for RSV

NanoBio Corporation announced today that it has received a $6M grant from the Bill & Melinda Gates Foundation to support the development of a safe and effective intranasal vaccine for Respiratory Syncytial Virus (RSV).

1 Dec 2010

Syneron launches CO2RE CO2 resurfacing system in US and Canada

Syneron Medical Ltd., the global leader in the medical aesthetic device marketplace, announced today the US Food and Drug Administration (FDA) and Health Canada clearance and commercial launch of its highly flexible CO2RE CO2 resurfacing system. CO2RE is a versatile fractional CO2 system that offers the unique ability to treat both superficial and deep skin layers simultaneously with precision-control over the intensity, pattern and depth of ablation.

30 Nov 2010

Acne News and Research

Latest Acne News and Research

Acupuncture and exercise help women with PCOS

Stiefel introduces BPO Acne Creamy Washes for OTC use in the U.S.

Palomar Medical Technologies to launch Acleara acne clearing system at AAD meeting

Proper skin care, cosmetics can improve skin of acne and rosacea patients

Positive results from Photocure's Allumera RevitAll study to improve skin's appearance

NINDS awards AndroScience $3.8M cooperative translational research grant for Kennedy's Disease

New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

Women with PCOS face high risk of type 2 diabetes due to aberrations in fat tissue

FDA accepts to review Fibrocell Science's azficel-T drug

Acne bacterium may also cause infections all over the body

KYTHERA and Intendis initiate ATX-101 European Phase III studies for reduction of submental fat

FDA approves Impax's ANDA for generic Doryx 75 and 100mg tablets

Study finds specially designed probiotic can prevent obesity

Fibrocell Science submits response to FDA CR letter for azficel-T BLA

Bayer's SAFYRAL oral contraceptive receives FDA approval

Boehringer Ingelheim reports positive results from afatinib phase IIb/III LUX-Lung 1 trial in advanced NSCLC

Cipher Phase 3 dermatology study uses MedAvante Centralized Ratings

NovaBay Pharmaceuticals, Galderma expand their multi-year collaboration agreement

Bill & Melinda Gates Foundation awards $6M grant to NanoBio to develop intranasal vaccine for RSV

Syneron launches CO2RE CO2 resurfacing system in US and Canada

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Acne News and Research

Latest Acne News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in